Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74660712 | 7466071 | 2 | F | 20100308 | 20160823 | 20100712 | 20160915 | EXP | US-ROCHE-713982 | ROCHE | 44.77 | YR | F | Y | 129.30000 | KG | 20160915 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74660712 | 7466071 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID: 1 | Y | 125085 | 2940 | MG | SOLUTION FOR INFUSION | ||||||
| 74660712 | 7466071 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID: 2 | Y | 125085 | 2850 | MG | SOLUTION FOR INFUSION | ||||||
| 74660712 | 7466071 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID: 3 | Y | 125085 | 2660 | MG | SOLUTION FOR INFUSION | ||||||
| 74660712 | 7466071 | 4 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | COURSE ID: 4 | Y | 125085 | 1300 | MG | SOLUTION FOR INFUSION | ||||||
| 74660712 | 7466071 | 5 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE ID: 1 | Y | 0 | 100 | MG | |||||||
| 74660712 | 7466071 | 6 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE ID: 2 | Y | 0 | 100 | MG | |||||||
| 74660712 | 7466071 | 7 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE ID: 3 | Y | 0 | 75 | MG | |||||||
| 74660712 | 7466071 | 8 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | COURSE ID: 4 | Y | 0 | 25 | MG | |||||||
| 74660712 | 7466071 | 9 | C | ALBUTEROL. | ALBUTEROL | 1 | 0 | ||||||||||||
| 74660712 | 7466071 | 10 | C | ATROVENT | IPRATROPIUM BROMIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 74660712 | 7466071 | 1 | Ovarian neoplasm |
| 74660712 | 7466071 | 5 | Ovarian neoplasm |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 74660712 | 7466071 | HO |
| 74660712 | 7466071 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 74660712 | 7466071 | Fatigue | |
| 74660712 | 7466071 | Hypoxia | |
| 74660712 | 7466071 | Pneumonitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |